Principal Financial Group
ABUS icon

Principal Financial Group’s Arbutus Biopharma ABUS Stock Holding History

Principal Financial Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59K Buy
12,298
+1,321
+12% +$5.8K ﹤0.01% 2127
2026
Q1 		$49.4K Buy
+10,977
New +$48K ﹤0.01% 2152
2025
Q4 		– Sell
-11,859
Closed -$53.8K – 2183
2025
Q3 		$53.8K Buy
11,859
+1,051
+10% +$3.86K ﹤0.01% 2211
2025
Q2 		$33.4K Sell
10,808
-720
-6% -$2.39K ﹤0.01% 2203
2025
Q1 		$40.2K Sell
11,528
-1,288
-10% -$4.29K ﹤0.01% 2128
2024
Q4 		$41.9K Sell
12,816
-939
-7% -$3.45K ﹤0.01% 2175
2024
Q3 		$53K Sell
13,755
-12,352
-47% -$47.4K ﹤0.01% 2174
2024
Q2 		$80.7K Sell
26,107
-15,341
-37% -$46K ﹤0.01% 2240
2024
Q1 		$107K Sell
41,448
-4,127
-9% -$10.7K ﹤0.01% 2266
2023
Q4 		$114K Sell
45,575
-25
-0.1% -$49 ﹤0.01% 2251
2023
Q3 		$92.6K Buy
45,600
+3,915
+9% +$8.21K ﹤0.01% 2294
2023
Q2 		$95.9K Buy
41,685
+2,603
+7% +$6.78K ﹤0.01% 2296
2023
Q1 		$118K Buy
39,082
+251
+0.6% +$708 ﹤0.01% 2277
2022
Q4 		$90.5K Buy
38,831
+24,800
+177% +$59.3K ﹤0.01% 2308
2022
Q3 		$27K Buy
14,031
+2,191
+19% +$5.16K ﹤0.01% 2443
2022
Q2 		$32K Buy
+11,840
New +$30.3K ﹤0.01% 2481

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Principal Financial Group's ABUS Position: Q2 2026 in Review

Principal Financial Group increased its Arbutus Biopharma (ABUS) stake by 12% in Q2 2026, buying an estimated $5.8K and bringing the position to 12,298 shares worth $59K. The position accounts for ﹤0.01% of the portfolio, ranked #2127.

Principal Financial Group first reported a position in ABUS in Q2 2022 and has held it in 16 quarters since. The position peaked at $118K in Q1 2023. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Principal Financial Group held 12,298 shares of Arbutus Biopharma worth $59K as of Q2 2026.
  • Principal Financial Group bought 1,321 Arbutus Biopharma shares in Q2 2026, an estimated $5.8K.
  • Arbutus Biopharma made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #2127 holding.
  • Principal Financial Group first reported a position in Arbutus Biopharma in Q2 2022 and has held it in 16 quarters since.
  • Principal Financial Group's Arbutus Biopharma position peaked at $118K in Q1 2023.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.